For the latest COVID-19 Travel restrictions and recommendations please click here


Protein biotherapeutics have gone from a seldom used subset of treatments to a multi-billion dollar global industry. With the ever-expanding protein therapeutic market, SMi's 6th annual Global Proteins Summit is well timed to investigate the latest developments in protein therapeutics, cell culture expression and immunogenicity.

The conference will explore the next generation of protein therapeutics, how they are being developed and reassess the technology, discovery and delivery trends. Also covered will be expression optimisation, case studies looking at successful drugs along with immunogenic considerations and safety assessment.

Reassess the latest therapeutics, developments, technologies, and methods that work in an interactive, networking friendly environment with major players from the biotech industry.

This meeting will feature talks from experts who will address:

  • Optimisation of pre-formulation approaches, expression and glycosylation
  • Next generation nanobodies
  • Generating therapeutic antibodies to multi-transmembrane receptors
  • Case studies in successful innovative biotherapeutics
  • In silico methods to reduce development risks
  • Recognising and combating immunogenicity
  • Regulatory perspectives

For speaker opportunities, contact smiproduction@smi-online.co.uk

For sponsorship and exhibitioning opportunities, contact  sponsorshipdept@smi-online.co.uk


Bernardo Perez-Ramirez
Senior Scientific Director, BioFormulations

Darren Hart
Team Leader
European Molecular Biology Laboratory (EMBL)

Dorothea Reilly
Senior Scientist and Associate Director

Paul Parren
Sr. Vice President, Research & Pre-Clinical Development

Jesús Zurdo 
Head of Advanced Protein Technologies
Lonza Biologics

See the full lineup...



CEOs, CSOs, CMOs, Vice Presidents, Presidents, Heads, Directors, Team Leaders, and Senior Scientists from the following roles:

  • Biochemistry
  • Biophysics
  • Clinical Affairs
  • Drug Surveillance/Product Safety
  • Gene expression
  • Immunogenicity / Immunology / Immune Response
  • International Clinical Safety
  • Marketing/Business Development
  • Medical Affairs
  • Medical Science
  • Molecular Biology
  • Non-clinical Research and Development
  • Pharmacovigilance
  • Project Management
  • Protein expression/purification
  • Proteomics
  • Quality Assurance
  • Regulatory Affairs
  • Scientific Affairs


Crowne Plaza St James Hotel

45-51 Buckingham Gate
 Tel: +44 (0) 207 834 6655
Fax: +44 (0) 207 6307
 Crowne Plaza St James Hotel

Crowne Plaza St James London is a traditional deluxe hotel right in the heart of the city, perfectly situated for all your business and leisure needs. In the heart of Westminster, it is just a stone's throw away from Buckingham Palace, The Houses of Parliament, the London Eye and Victoria Station.  

The hotel boasts three excellent restaurants. Bistro 51 with British and European cuisine, the Michelin Starred Indian restaurant Quilon serving south coastal Indian food and Bank Westminster with a modern British menu.

A beautiful, award-winning, courtyard garden surrounds the Victorian buildings of the Crowne Plaza London St James - a peaceful oasis in the centre of London.

Crowne Plaza St James


Book your accommodation at SMi discounted rates by:

SMi discounted rates include Continental Breakfast & VAT
  • £ 205.63 / Standard room / night for single occupancy
  • £ 229.13 Executive  room / night for single occupancy


Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Bernardo Perez-Ramirez

Bernardo Perez-Ramirez, Senior Scientific Director, BioFormulations Development, Genzyme Corporation

9:10 Optimizing Pre-formulation Approaches for Successful Development of Therapeutic Proteins

Bernardo Perez-Ramirez

Bernardo Perez-Ramirez, Senior Scientific Director, BioFormulations Development, Genzyme Corporation

  • Early assessment of "developmentability" potential
  • Maximizing data collection and output with minimal amount of protein
  • Global analysis and thermodynamic assessment
  • Choosing proper stress conditions
  • 9:50 Multi-Specific Adnectins

    Ray Camphausen

    Ray Camphausen, Associate Vice President of Protein Design, Adnexus, a Bristol-Myers Squibb R&D Company

  • Advantages compared to traditional targeted biologics
  • Challenges in modulating two distinct targets
  • Engineering and optimisation
  • Clinical potential
  • 10:30 Morning Coffee

    11:00 DARPin Therapeutics

    H. Kaspar Binz

    H. Kaspar Binz, Vice President Technology, Molecular Partners A G

  • Combining the favourable properties of antibodies with those of small molecule drugs
  • Engineering of novel types of drugs superior to currently known biologics
  • Updates on MP0112, a best-in-class therapeutic DARPin for the treatment of ocular neovascularization diseases
  • 11:40 Case Study: Arzerra (Ofatumumab)

    Paul Parren

    Paul Parren, Senior Vice President, Research & Pre-Clinical Development, Genmab B.V.

  • Introduction to CD20 and Arzerra
  • Mechanism of action of tumour cell killing activity in vitro and in vivo
  • Update on progress in the clinic
  • 12:20 Networking Lunch

    13:20 Next Generation Nanobodies

    Serge Muyldermans

    Serge Muyldermans, Professor, Department of Molecular and Cellular Interactions, Vrije Universiteit Brussel

  • Distinct structural and functional properties
  • Advantages over other designed target binders
  • Engineering to broaden utility
  • Future therapeutics
  • 14:00 MetMAb: One-Armed 5D5 Anti-c-Met Antibody

    Dorothea Reilly

    Dorothea Reilly, Senior Scientist, Genentech

  • Optimising the level of foreign gene expression
  • Background
  • Production issues and solutions
  • Optimisation
  • Future novel molecules
  • 14:40 Anticalins®

    Andreas Hohlbaum

    Andreas Hohlbaum, CTO, Pieris Proteolab AG

  • Modified human lipocalins as unique scaffold
  • PRS-050 (VEGF antagonist) entering human studies
  • Anticalins against hapten targets
  • Formulation and formatting flexibility
  • CMC advantages
  • Alternative delivery
  • 15:20 Afternoon Tea

    15:50 Alternates Approaches to Preclinical Safety Assessment of Biologics: Case Studies

    Rakesh Dixit

    Rakesh Dixit, Global Head, Biologics Safety Assessment & Exp. Pathology, Medimmune

  • Selecting the right animal model to test toxicology
  • Alternatives to in vivo animal testing
  • Looking ahead
  • 16:30 Soluble Fc Receptor (SM101) for the treatment of autoimmune diseases

    Peter Sondermann

    Peter Sondermann, CSO, SuppreMol GmbH

  • Inclusion body based expression in E. coli & subsequent refolding of SM101 were optimised to a high yield process
  • The production method allows a tag-free purification
  • SM101 has finished a Phase I study in healthy volunteers
  • Clinical development in autoimmune diseases is ongoing
  • 17:10 Chairman’s Closing Remarks and Close of Day One

    Rakesh Dixit

    Rakesh Dixit, Global Head, Biologics Safety Assessment & Exp. Pathology, Medimmune

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Darren Hart

    Darren Hart, Team Leader, European Molecular Biology Laboratory

    9:10 Library-Based Construct Screening

    Darren Hart

    Darren Hart, Team Leader, European Molecular Biology Laboratory

  • Directed evolution strategies for protein expression
  • ESPRIT (Expression of Soluble Proteins by Random Incremental Truncation)
  • Expression analysis using high throughput robotics
  • Case study: expression, purification and structural studies on drug targets & vaccine candidates
  • 9:50 High-Throughput Eukaryotic Protein Expression

    Opher Gileadi

    Opher Gileadi, Principal Investigator, Oxford University

    Optimizing the level of foreign gene expression
    The impact of protein engineering
    Expression of human integral membrane proteins

    10:30 Morning Coffee

    11:00 Protein Tools for Drug Discovery; Lessons Learnt

    Ian Hunt

    Ian Hunt, Group Leader, Protein Production Group, Novartis Institutes for BioMedical Research

  • Technologies and innovations
  • Accelerating the generation of recombinant proteins for small molecule drug discovery
  • Tricks of the trade - expression of difficult to make protein
  • 11:40 New ways of Establishing Production Cell Lines for Structural Biology

  • Site-specific recombination allows shuttling of genes of interest to favourable genetic loci
  • Preparative FACS of GFP positive cells identifies highly productive and genetically stable clones
  • Glycosylation deficient CHO lines produce homogenous glycoproteins
  • The resulting glycoproteins can be deglycosylated enzymatically and crystallized efficiently
  • Konrad Büssow

    Konrad Büssow, Head of Mammalian Protein Expression Group, Helmholtz Centre For Infection Research

    12:20 Networking Lunch

    13:20 Optimising Glycosylation for Antibody Therapeutics

    Roy Jefferis

    Roy Jefferis, Professor of Molecular Immunology, University Of Birmingham

  • Co- and post- translational modifications
  • Antibody therapeutics as autoantibodies
  • Immune complexes/aggregation
  • Cell engineering & glycoform profiles
  • Human IgG subclasses & polymorphisms
  • 14:00 In silico Methods to Reduce Development Risks in Biotherapeutics

    Jesús Zurdo

    Jesús Zurdo, Head of Advanced Protein Technologies, Lonza Biologics plc

  • Development challenges in biopharmaceuticals. Aggregation and stability issues
  • Upstream risk assessment to improve potential outcome of projects
  • Opportunities for designing quality in the product & expand the DSP design space
  • In silico aggregation prediction, opportunities for selection of optimal leads
  • Engineering biopharmaceuticals for improved developability
  • 14:40 Immunogenicity Aspects & Risk-Based Approaches

    Arno Kromminga

    Arno Kromminga, CEO, IPM BIOTECH GmbH

  • Novel proteins as foreign antigens
  • Allergic risk factors
  • Clinical consequences of ADA
  • 15:20 Afternoon Tea

    15:50 Generation of Therapeutic Antibodies against Inflammatory Disease and Cancer Targets

    Matthew Baker

    Matthew Baker, CEO & CSO, Antitope

  • Problem of anti-therapeutic antibody responses
  • Importance of ex vivo T cell epitope mapping
  • Engineering proteins to avoid T cell epitopes
  • 16:30 Regulatory Guidance - an EU Perspective

    Meenu Wadhwa

    Meenu Wadhwa, Head, Cytokines & Growth Factors & Biotherapeutics, National Institute For Biological Standards And Control

  • Existing and Upcoming EMEA guidelines
  • Comparing immunogenicity
  • Best practices and common problems with immunogenicity assessment
  • 17:10 Chairman’s Closing Remarks and Close of Day Two



    Immunogenicity Programs: Not Just Another Box to Check

    Immunogenicity Programs: Not Just Another Box to Check

    Crowne Plaza Hotel - St James
    22nd June 2010
    London, United Kingdom

    Crowne Plaza Hotel - St James

    Buckingham Gate 45/51
    London SW1E 6AF
    United Kingdom

    Crowne Plaza Hotel - St James



    speaker image






    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.


    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.


    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.


    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title


    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event


    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71

    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out